NEO vs TMO

For growth investors, NeoGenomics, Inc.

(NEO) is the stronger pick with 10. 1% revenue growth year-over-year, versus 3. 9% for Thermo Fisher Scientific Inc. (TMO). Thermo Fisher Scientific Inc. (TMO) offers the better valuation at 26. 5x trailing P/E (18. 9x forward), making it the more compelling value choice. Analysts rate NeoGenomics, Inc. (NEO) a "Buy" — based on 29 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Thermo Fisher Scientific Inc.

is actually cheaper at 18. 9x.

Over the past 5 years, Thermo Fisher Scientific Inc.

(TMO) delivered a total return of +1. 4%, compared to -74. 4% for NeoGenomics, Inc. (NEO). Over 10 years, the gap is even starker: TMO returned +219. 0% versus NEO's +42. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Thermo Fisher Scientific Inc.

(TMO) is the lower-risk stock at 0. 91β versus NeoGenomics, Inc. 's 1. 37β — meaning NEO is approximately 51% more volatile than TMO relative to the S&P 500. On balance sheet safety, NeoGenomics, Inc. (NEO) carries a lower debt/equity ratio of 56% versus 76% for Thermo Fisher Scientific Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), NeoGenomics, Inc.

(NEO) is pulling ahead at 10. 1% versus 3. 9% for Thermo Fisher Scientific Inc. (TMO). On earnings-per-share growth, the picture is similar: Thermo Fisher Scientific Inc. grew EPS 7. 3% year-over-year, compared to -35. 5% for NeoGenomics, Inc.. Over a 3-year CAGR, NEO leads at 12. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Thermo Fisher Scientific Inc.

(TMO) is the more profitable company, earning 15. 1% net margin versus -14. 9% for NeoGenomics, Inc. — meaning it keeps 15. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TMO leads at 18. 2% versus -9. 1% for NEO. At the gross margin level — before operating expenses — NEO leads at 38. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Thermo Fisher Scientific Inc.

(TMO) trades at 18. 9x forward P/E versus 61. 9x for NeoGenomics, Inc. — 43. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NEO: 70. 4% to $19. 00.

In this comparison, TMO (0.

4% yield) pays a dividend. NEO does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Thermo Fisher Scientific Inc.

(TMO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 91), +219. 0% 10Y return). Both have compounded well over 10 years (TMO: +219. 0%, NEO: +42. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.